Contact Us
  • Choose License Type

The global clostridium difficile diagnostics and treatment market by Product Type (By Drug (Metronidazole, Vancomycin, Fidaxomicin, and Bezlotoxumab), By Diagnostic Test (Enzyme Immunoassays, Real-Time Polymerase Chain Reaction (RT-PCR), Nucleic Amplification Tests (NAAT), and Others)), By Distribution Channel (Hospitals & Clinics, Diagnostic Laboratories, and Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 1,272.2 million in 2016 and is projected to exhibit a CAGR of 8.2% over the forecast period (2017–2025). 

Clostridium difficile infection diagnostics and treatment market is expected to witness significant growth over the forecast period, due to increased antibiotic consumption resulting in damage to natural flora, which creates a conducive environment for growth of C.difficile bacterium. Furthermore, factors such as presence of sensitive and easily accessible diagnostic tests, and availability of generic antibiotics (metronidazole, and Vancomycin), and is expected to fuel growth of the clostridium difficile diagnostics and treatment market.

Prevalence of clostridium difficile infection is increasing, and it is the most common healthcare-associated infection according to Center for Disease Control & Prevention (CDC), 2015. In order to cater to increasing demand for drugs, generic manufacturers have capitalized on patent losses of standard antibiotics for the treatment of clostridium difficile infection such as metronidazole and vancomycin. Lupin Ltd., Sandoz, Inc., Mylan Laboratories Ltd., and others offer generic version of these antibiotics. Furthermore, manufacturers are developing novel therapies such as monoclonal antibodies for the treatment of this disease. For instance, the U.S. Food & Drug Administration approved Merck & Co., Inc.’s Zinplava (Bezlotoxumab) in 2016, indicated for prevention of recurrence of CDI, and the company launched Zinplava in the U.K. in January 2018. CutisPharma launched FIRVANQ (vancomycin hydrochloride), an oral solution, in April 2018. Increasing research and development of alternative therapies such as microbiome therapeutics and vaccines (by Pfizer, Inc., and Valneva) is expected to positively impact growth of the clostridium difficile treatment market over the forecast period.

Browse 37 Market Data Tables and 43 Figures spread through 172 Pages and in-depth TOC on Clostridium Difficile Diagnostics and Treatment Market by Product Type (By Drug (Metronidazole, Vancomycin, Fidaxomicin, and Bezlotoxumab), By Diagnostic Test (Enzyme Immunoassays, Real-Time Polymerase Chain Reaction (RT-PCR), Nucleic Amplification Tests (NAAT), and Others)), By Distribution Channel (Hospitals & Clinics, Diagnostic Laboratories, and Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and, Africa) - Global Forecast to 2025.

To know the latest trends and insights prevalent in the Clostridium Difficile Diagnostics and Treatment Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/clostridium-difficile-diagnostics-and-treatment-market-1499

Diagnostics manufacturers are focusing on offering sensitive diagnostic tests for rapid diagnosis of clostridium difficile infection. HiberGene Diagnostics received CE mark for HG C. difficile test in 2016 and DiaSorin Molecular launched clostridium difficile molecular test in 2016. GenePOC, Inc. received the U.S. Food & Drug Administration approval for its GenePOC Cdiff molecular test in the U.S. in 2017. Furthermore, bioMérieux launched Vidas C. difficile toxin A&B, the first automated detection test for clostridium difficile A and B toxins, in 2017. Organizations and manufacturers are working towards increasing awareness about clostridium difficile infection.  CutisPharma and C Diff Foundation announced plans to enter into partnership to increase clostridium difficile awareness among populace, in 2017. Moreover, in March 2018, C Diff Foundation awarded its “Making a Difference” award to CutisPharma, Inc., for its contribution in increasing awareness regarding clostridium difficile awareness.

Key Takeaways of the Clostridium Difficile Diagnostics and Treatment Market:

  • The global clostridium difficile diagnostics and treatment market is expected to exhibit a CAGR of 2% over the forecast period (2017–2025), owing to rising prevalence of the disease. For instance, around half a million people in the U.S. suffer from clostridium difficile infection in a year, according to Centers for Disease Control and Prevention (CDC), 2015.
  • Manufacturers are focusing on research and development of alternative therapies such as vaccines and microbiome therapeutics, which is expected to aid in market growth over the forecast period
  • Manufacturers are focusing on developing more sensitive and accurate diagnostic test such as polymerase chain reaction based assays, and point-of-care diagnostics for C. difficile which is expected to aid in growth of the market
  • Asia Pacific market is expected to witness significant growth, owing to presence of generic players such as Cipla and Lupin that offer generics for C. difficile
  • Major players operating in the clostridium difficile diagnostics and treatment market include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Abbott Laboratories, Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, and AstraZeneca Plc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner